Jose M Jimeno
Overview
Explore the profile of Jose M Jimeno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bouhaddou M, Reuschl A, Polacco B, Thorne L, Ummadi M, Ye C, et al.
Cell
. 2023 Sep;
186(21):4597-4614.e26.
PMID: 37738970
SARS-CoV-2 variants of concern (VOCs) emerged during the COVID-19 pandemic. Here, we used unbiased systems approaches to study the host-selective forces driving VOC evolution. We discovered that VOCs evolved convergent...
2.
Varona J, Landete P, Paredes R, Vates R, Torralba M, Guisado-Vasco P, et al.
Front Cell Infect Microbiol
. 2023 Mar;
13:1097809.
PMID: 36909731
Introduction: The APLICOV-PC study assessed the safety and preliminary efficacy of plitidepsin in hospitalized adult patients with COVID-19. In this follow-up study (E-APLICOV), the incidence of post-COVID-19 morbidity was evaluated...
3.
Varona J, Landete P, Lopez-Martin J, Estrada V, Paredes R, Guisado-Vasco P, et al.
Life Sci Alliance
. 2022 Jan;
5(4).
PMID: 35012962
Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over...
4.
Varona J, Landete P, Lopez-Martin J, Estrada V, Paredes R, Guisado-Vasco P, et al.
medRxiv
. 2021 Jun;
PMID: 34075384
One-sentence Summary: Plitidepsin, an inhibitor of SARS-Cov-2 , is safe and positively influences the outcome of patients hospitalized with COVID-19.
5.
Barboza N, Medina D, Budak-Alpdogan T, Aracil M, Jimeno J, Bertino J, et al.
Cancer Biol Ther
. 2012 Feb;
13(2):114-22.
PMID: 22336911
Plitidepsin (Aplidin), an antitumor agent of marine origin, presently is undergoing phase II/III clinical trials, and has shown promise for the treatment of lymphoma. Here, we describe the antitumor effects...
6.
Rademaker-Lakhai J, Horenblas S, Meinhardt W, Stokvis E, de Reijke T, Jimeno J, et al.
Clin Cancer Res
. 2005 Mar;
11(5):1854-62.
PMID: 15756010
Purpose: The purpose is to determine the maximum tolerated dose, profile of adverse events, and dose-limiting toxicity of Kahalalide F (KF) in patients with androgen refractory prostate cancer. Furthermore, the...
7.
Sparidans R, Schellens J, Lopez-Lazaro L, Jimeno J, Beijnen J
Biomed Chromatogr
. 2004 Feb;
18(1):16-20.
PMID: 14872544
A sensitive bio-analytical assay for the depsipeptide aplidine in plasma has been modified and tested for human whole blood samples. The adapted method is based on reversed-phase liquid chromatography and...
8.
Jimeno J
Anticancer Drugs
. 2002 Aug;
13 Suppl 1:S15-9.
PMID: 12173490
The sea, covering 70% of the Earth's surface, offers a considerably broader spectrum of biological diversity than terra firma. Containing approximately 75% of all living organisms, the marine environment offers...